Safety and tolerability of GLP-1 receptor agonists

Berta Soldevila; Manel Puig-Domingo

doi:10.1016/S0025-7753(14)70107-1

Safety and tolerability of GLP-1 receptor agonists

Berta Soldevila, Manel Puig-Domingo

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

Copyright © 2014 Elsevier España, S.L.U. All rights reserved. Glucagon-like peptide-1 receptor agonists (GLP-1ra) are a new group of drugs with a glucose-lowering action due to their incretin effect. The GLP-1 receptor is expressed in various human tissues, which could be related to the pleiotropic effects of human GLP-1, as well as to the adverse effects described in patients treated with GLP-1ra. The risk of hypoglycaemia is low, which is one of the main considerations in the safety of this family of compounds and is also important to patients with diabetes. The most frequent adverse effect is nausea, which usually occurs at the start of treatment and is transient in 20-60% of affected patients. This article also reviews the information available on antibody formation, the potential effect on the thyroid gland, and the controversial association between this group of drugs with pancreatitis and cancer.

Original language	English
Pages (from-to)	35-40
Journal	Medicina clínica
Volume	143
DOIs	https://doi.org/10.1016/S0025-7753(14)70107-1
Publication status	Published - 1 Sept 2014

Keywords

Antibodies
Anticuerpos
Cancer
Cardiovascular
Cáncer
Gastrointestinal
GLP-1
Hipoglucemia
Hypoglycemia
Local reactions
Pancreatitis
Reacciones locales
Safety
Seguridad
Thyroid gland
Tiroides
Tolerability
Tolerancia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0025-7753(14)70107-1

Cite this

@article{41ad7ebfe76d4350821e9d0e86920087,

title = "Safety and tolerability of GLP-1 receptor agonists",

abstract = "Copyright {\textcopyright} 2014 Elsevier Espa{\~n}a, S.L.U. All rights reserved. Glucagon-like peptide-1 receptor agonists (GLP-1ra) are a new group of drugs with a glucose-lowering action due to their incretin effect. The GLP-1 receptor is expressed in various human tissues, which could be related to the pleiotropic effects of human GLP-1, as well as to the adverse effects described in patients treated with GLP-1ra. The risk of hypoglycaemia is low, which is one of the main considerations in the safety of this family of compounds and is also important to patients with diabetes. The most frequent adverse effect is nausea, which usually occurs at the start of treatment and is transient in 20-60% of affected patients. This article also reviews the information available on antibody formation, the potential effect on the thyroid gland, and the controversial association between this group of drugs with pancreatitis and cancer.",

keywords = "Antibodies, Anticuerpos, Cancer, Cardiovascular, C{\'a}ncer, Gastrointestinal, GLP-1, Hipoglucemia, Hypoglycemia, Local reactions, Pancreatitis, Reacciones locales, Safety, Seguridad, Thyroid gland, Tiroides, Tolerability, Tolerancia",

author = "Berta Soldevila and Manel Puig-Domingo",

year = "2014",

month = sep,

day = "1",

doi = "10.1016/S0025-7753(14)70107-1",

language = "English",

volume = "143",

pages = "35--40",

journal = "Medicina Clinica",

issn = "0025-7753",

}

TY - JOUR

T1 - Safety and tolerability of GLP-1 receptor agonists

AU - Soldevila, Berta

AU - Puig-Domingo, Manel

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Copyright © 2014 Elsevier España, S.L.U. All rights reserved. Glucagon-like peptide-1 receptor agonists (GLP-1ra) are a new group of drugs with a glucose-lowering action due to their incretin effect. The GLP-1 receptor is expressed in various human tissues, which could be related to the pleiotropic effects of human GLP-1, as well as to the adverse effects described in patients treated with GLP-1ra. The risk of hypoglycaemia is low, which is one of the main considerations in the safety of this family of compounds and is also important to patients with diabetes. The most frequent adverse effect is nausea, which usually occurs at the start of treatment and is transient in 20-60% of affected patients. This article also reviews the information available on antibody formation, the potential effect on the thyroid gland, and the controversial association between this group of drugs with pancreatitis and cancer.

AB - Copyright © 2014 Elsevier España, S.L.U. All rights reserved. Glucagon-like peptide-1 receptor agonists (GLP-1ra) are a new group of drugs with a glucose-lowering action due to their incretin effect. The GLP-1 receptor is expressed in various human tissues, which could be related to the pleiotropic effects of human GLP-1, as well as to the adverse effects described in patients treated with GLP-1ra. The risk of hypoglycaemia is low, which is one of the main considerations in the safety of this family of compounds and is also important to patients with diabetes. The most frequent adverse effect is nausea, which usually occurs at the start of treatment and is transient in 20-60% of affected patients. This article also reviews the information available on antibody formation, the potential effect on the thyroid gland, and the controversial association between this group of drugs with pancreatitis and cancer.

KW - Antibodies

KW - Anticuerpos

KW - Cancer

KW - Cardiovascular

KW - Cáncer

KW - Gastrointestinal

KW - GLP-1

KW - Hipoglucemia

KW - Hypoglycemia

KW - Local reactions

KW - Pancreatitis

KW - Reacciones locales

KW - Safety

KW - Seguridad

KW - Thyroid gland

KW - Tiroides

KW - Tolerability

KW - Tolerancia

U2 - 10.1016/S0025-7753(14)70107-1

DO - 10.1016/S0025-7753(14)70107-1

M3 - Article

SN - 0025-7753

VL - 143

SP - 35

EP - 40

JO - Medicina Clinica

JF - Medicina Clinica

ER -

Safety and tolerability of GLP-1 receptor agonists

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this